Table S4: Genes more than 2-fold down-regulation in hESC derived enriched cardiomyocytes (CM) compared with ES and EB; Fold change is caculated as mean of 3 replicates

Table S8b.cardiac-enriched genes involved in functional categories; this table refers to genes in PPAR signaling pathway

Table S9A Cardiomyocyte specific genes identified by 3 studies (Beqqali et al  Synnergren  and this study)

Table S8a.cardiac-enriched genes involved in functional categories; this table refers to genes in cardiac transcription network

Table S5: Genes more than 2-fold up-regulation in hESC derived enriched cardiomyocytes (CM)  fetal heart (FH) and adult heart (AH); Fold change is caculated as mean of 3 replicates

Table S8c.cardiac-enriched genes involved in functional categories; this table refers to sarcomere genes

Table S8d.cardiac-enriched genes involved in functional categories; this table refers to ion transport genes

Table 4. Hsa-miR-129 expression data in lymph node positive (LNP) and lymph node negative (LNN) groups

Table 5. Hsa-miR-137 expression data in lymph node positive (LNP) and lymph node negative (LNN) groups

Table 3. Differentially expressed microRNA in lymph node positive (LNP) group compared with the lymph node negative (LNN) group

Table I. Chromosomal Localization  Mean Standard Deviation (SD)  Range  Percentile 25 (P25)  Median (P50)  and Percentile 75 (P75) of the Expression Values of the Different Drug Resistance Genes in ALL

Table 1. Genes used for building a tumour cell percentage associated profile.

Additional File 1-3. A list of genes corresponding to certain breast cancer related pathways; BRCA1-dependent Ub-ligase activity;

Additional file 2. Probe sets on the pathways. The probe identifiers for the genes listed in the five breast cancer related pathways

2. ER-associated degradation (ERAD) Pathway

Additional File 1-5. A list of genes corresponding to certain breast cancer related pathways;Cell Cycle: G2/M Checkpoint

Additional File 1-4. A list of genes corresponding to certain breast cancer related pathways;Cell Cycle: G1/S Check Point